Phase I Alexander study of AUTO3, the first CD19/22 dual targeting CAR T cell therapy, with pembrolizumab in patients with relapsed/refractory (r/r) DLBCL.Wendy Osborne, Kirit M. Ardeshna, Maria A. V. Marzolini et al.|Journal of Clinical Oncology|2020Cited by 45
Survival outcomes of allogeneic hematopoietic cell transplants with EBV‐positive or EBV‐negative post‐transplant lymphoproliferative disorder, A CIBMTR studySeema Naik, Rammurti T. Kamble, Min Chen et al.|Transplant Infectious Disease|2019Cited by 27
890MO Phase I Alexander study of AUTO3, the first CD19/22 dual targeting CAR.T cell, with pembrolizumab in patients with relapsed/refractory (r/r) DLBCLEleni Tholouli, K. Ardesha, Wendy Osborne et al.|Annals of Oncology|2020Cited by 4
529 Targeting SIRT1 Activity: a Novel Strategy for Acute Myeloid Leukemia TherapySteffan T. Nawrocki, Jennifer S. Carew, Kathleen Kelly et al.|European Journal of Cancer|2012Cited by 0